Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Conference Call December 7, 2023 4:30 PM ET

Company Participants

Sanjay Hurry - Head of IR

Beth Jantzen - CFO

James Hayward - Chairman, President and CEO

Clay Shorrock - Chief Legal Officer and Head of Business Development

Conference Call Participants

Jason McCarthy - Maxim Group

Yi Chen - H.C. Wainwright

Operator

Good Day and welcome to the Applied DNA Sciences Fiscal Fourth Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Sanjay Hurry, Head of Investor Relations. Please go ahead.

Sanjay Hurry

Thank you, Vaishnavi. Good afternoon everyone, and welcome to Applied DNA's conference call to discuss our fourth quarter fiscal 2023 financial results. You can access the press release that was issued after market close today as well as the slide presentation accompanying this call on the Investor Relations section of our corporate website. Speaking on the call today are Dr. James Hayward, our Chairman, President, and CEO; Beth Jantzen, our CFO; and Clay Shorrock, our Chief Legal Officer and Head of Business Development. Judy Murrah, Our COO, will also be available to answer questions on the Q&A portion of today's call.

Before we begin, please note that some of the information you will hear today during our discussion may consist of forward-looking statements. I refer you to Slide 2 of the presentation and our Form 10-K filed a short while ago for important risk factors that could cause the company's actual performance and results to differ materially from those expressed or implied in any forward-looking statements. We undertake no obligation to update or revise any forward-looking statements or other information provided on this call as a result of new information or future results or developments.

Now it's my pleasure to introduce our first speaker on today's call, Beth Jantzen. Please go ahead, Beth.

Beth Jantzen

Thank you, Sanjay. Good afternoon, everyone. Thank you for joining us on our fiscal fourth quarter investor call. I will start this afternoon with an overview of our results for the quarter ended September 30, 2023. I will then turn the call over to Dr. James Hayward, our President and CEO, who will update you on our ongoing business initiatives. We will then open the line for questions from our analysts and institutional investors.

To preface the year over year comparison of our fiscal 2023 fourth quarter results, I highlight that the year ago period included robust COVID-19 testing-related revenues, as well as a cotton tagging revenue that are not present in the quarter being reported today. The cotton order for the current ginning season was received and shipped subsequent to 9/30. As Clay and Jim will speak to later, fiscal 2023 was an important building year for the company that we believe lays the foundation for our future growth in the manufacturing of DNA for biotherapeutic applications.